Beranda › Kanker Lambung › Michigan
Uji klinis Kanker Lambung di Michigan
35 studi untuk Kanker Lambung mencari peserta di lokasi di Michigan.
Kota di Michigan
- Grand Rapids18 studi
- Detroit16 studi
- Ann Arbor8 studi
- Farmington Hills4 studi
- Lansing3 studi
- Livonia3 studi
- Warren3 studi
- Canton3 studi
- Clinton Township3 studi
Teks studi resmi (Bahasa Inggris)
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health IHA - Obstetrics and Gynecology West Arbor, Ann Arbor
- dan 50 lainnya
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07283939Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- dan 68 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Profound Research -OMG - TriAtria Cancer Center, Farmington Hills
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06760819Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Henry Ford Health, Detroit
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07700979A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
- Research Site, North Shores
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07069712Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Grand Rapids
Menerima pesertaFase 2
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- START Midwest, Grand Rapids
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Barbara Ann Karmanos Cancer Institute, Detroit
- BAMF Health Inc., Grand Rapids
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07114601A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Barbara Ann Karmanos Cancer Institute, Detroit
- BAMF Health Inc., Grand Rapids
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213791Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- START Midwest, Grand Rapids
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT05267626Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Karmanos Cancer Institiute, Detroit
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- University of Michigan, Ann Arbor
- Henry Ford Cancer Institute, Detroit
- START - Midwest Cancer Research Center, Grand Rapids
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06253871Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Grand Rapids
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07431281The Vanguard Study: Testing a New Way to Screen for Cancer
- Henry Ford Cancer Institute-Downriver, Brownstown
- Henry Ford Health Center - Brownstown, Brownstown
- Henry Ford Health Center - Chesterfield, Chesterfield
- dan 13 lainnya
Menerima pesertaSukarelawan sehat diterima
Usia 45 hingga 75 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06995898A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Brigitte Harris Cancer Pavilion BHCP, Detroit
- START Midwest, LLC, Grand Rapids
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07070232A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Grand Rapids
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT07115043A Study of MGC026 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT06242470A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- University of Michigan Comprehensive Cancer Center Michigan Medicine, Ann Arbor
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT06731478Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Henry Ford Cancer Institute, Detroit
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT04198766Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #120, Detroit
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jul 2026 · NCT06974110A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
- Karmanos Cancer Institute, Farmington Hills
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT05208762A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- START Midwest, Grand Rapids
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06131840A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Henry Ford Health System, Detroit
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT06657144Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
- University of Michigan Rogel Cancer Center, Ann Arbor
Menerima pesertaFase 4
Usia 18 ke atas · Wanita · Diperbarui 2 Jul 2026 · NCT05183126Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- START Midwest /ID# 248685, Grand Rapids
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT05005403Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
- BAMF Health, Grand Rapids
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT07219238BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- University of Michigan, Ann Arbor
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT05768932Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Research Site, Grand Rapids
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Mei 2026 · NCT05702229Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
- Henry Ford Cancer-Detroit, Detroit
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Des 2025 · NCT06065371A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- START Midwest, Grand Rapids
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Des 2025 · NCT06943521SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Ann Arbor
- Massive Bio SYNERGY-AI site, Lansing
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- University of Michigan, Ann Arbor
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2025 · NCT0594150764Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- BAMF Health, Inc., Grand Rapids
Menerima pesertaFase 1/2
Usia 15 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2025 · NCT06298916A Beta-only IL-2 ImmunoTherapY Study
- Karmanos Cancer Institute, Detroit
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2025 · NCT05086692Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.